Get the Latest Updates
with Juniper Biosciences

Juniper Biosciences Unveils JBS-002 and JBS-004, Advancing Two Late-Stage Diagnostic Programs to Registration Batch Manufacturing in the Fourth Quarter of 2026

Prostate cancer and Alzheimer’s disease imaging programs position the Company for FDA submissions in 2027 across two of...

MSKCC announces FDA Breakthrough Therapy Designation for JBS-003 & Details Impact to Patients

FDA Reviewing Low-Dose Radiation To Treat HPV Throat Cancer With Fewer Side Effects

By Jim Stallard, Thursday, September 3, 2026

Juniper’s JBS-003 (F-MISO) Program Receives FDA Breakthrough Therapy Designation, Advancing a First-in-Class Hypoxia Tracer Enabling Radiation De-escalation in HPV-Positive Head and Neck Cancer

BEDMINSTER, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) — Juniper Biosciences today announced that the U.S. Food and Drug...